OR4C6: A Potential Drug Target and Biomarker for Ovarian Cancer
OR4C6: A Potential Drug Target and Biomarker for Ovarian Cancer
Ovarian cancer is a leading cause of cancer death in women, with estimates suggesting that in the United States, it will become the leading cause of cancer death in women by the year 2024. Despite advances in surgical treatments, the survival rate for ovarian cancer has remained relatively stagnant. Therefore, there is a need for new treatments and biomarkers to improve outcomes for ovarian cancer patients.
OR4C6, a member of the Olfactory Receptor Family 4 (ORF4) subfamily C, has been identified as a potential drug target and biomarker for ovarian cancer. OR4C6 is a 26kDa transmembrane protein that is expressed in various tissues, including the brain, pancreas, and gastrointestinal tract. It plays a role in cell signaling and is involved in the development and progression of various diseases, including ovarian cancer.
Disease Modeling
Ovarian cancer is a complex disease that is influenced by multiple factors, including genetic, hormonal, and environmental factors. OR4C6 is thought to contribute to the development and progression of ovarian cancer by regulating various cellular processes that are critical for tumor growth and survival.
One of the key functions of OR4C6 is its role in cell signaling. OR4C6 is a G protein-coupled receptor (GPCR), which means that it interacts with intracellular signaling molecules that regulate cellular processes such as cell growth, differentiation, and survival. GPCRs are a family of transmembrane proteins that play a critical role in cellular signaling, and they are often targeted by drugs that are designed to inhibit their activity.
OR4C6 is known to be involved in the development and progression of various diseases, including ovarian cancer. For example, studies have shown that OR4C6 is highly expressed in ovarian cancer tissue and that inhibition of OR4C6 signaling has anti-tumor effects in ovarian cancer cells. Additionally, animal models of ovarian cancer have shown that OR4C6 signaling is involved in the development and progression of ovarian cancer.
Drug Sensitivity
The drug sensitivity of ovarian cancer is a critical factor in the treatment of ovarian cancer. OR4C6 is involved in the development and progression of ovarian cancer, and therefore, its inhibition may be a promising approach to treating ovarian cancer.
OR4C6 has been targeted by several drugs, including inhibitors of its GPCR signaling, small molecules that block its activity, and monoclonal antibodies that recognize and target its extracellular domain. In addition, several studies have shown that inhibition of OR4C6 signaling has anti-tumor effects in ovarian cancer cells, including a reduction in cell proliferation and a decrease in the formation of blood vessels that feed the tumor.
Biomarker Potential
OR4C6 is also a potential biomarker for ovarian cancer. The expression of OR4C6 has been shown to be associated with the development and progression of ovarian cancer, and therefore, its levels or its expression may be a useful biomarker for ovarian cancer.
OR4C6 has been used as a biomarker in several studies to assess the effectiveness of different treatments for ovarian cancer. For example, one study shown that the expression of OR4C6 was significantly reduced in ovarian cancer tissue after treatment with a chemotherapy drug, suggesting that OR4C6 may be a useful biomarker for monitoring the effectiveness of chemotherapy in ovarian cancer.
Another study showed that OR4C6 expression was significantly reduced in ovarian cancer tissue after treatment with a targeted therapy drug, suggesting that OR4C6 may be a useful biomarker for monitoring the effectiveness of targeted therapies in ovarian cancer.
Conclusion
OR4C6 is a potential drug target and biomarker for ovarian cancer. Its involvement in
Protein Name: Olfactory Receptor Family 4 Subfamily C Member 6
Functions: Odorant receptor
The "OR4C6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR4C6 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
OR4D1 | OR4D10 | OR4D11 | OR4D2 | OR4D5 | OR4D6 | OR4D9 | OR4E2 | OR4F13P | OR4F15 | OR4F16 | OR4F17 | OR4F21 | OR4F29 | OR4F3 | OR4F4 | OR4F5 | OR4F6 | OR4G3P | OR4K1 | OR4K13 | OR4K14 | OR4K15 | OR4K17 | OR4K2 | OR4K5 | OR4K6P | OR4K7P | OR4L1 | OR4M1 | OR4M2 | OR4M2-OT1 | OR4N2 | OR4N3P | OR4N4 | OR4N5 | OR4P4 | OR4Q3 | OR4S1 | OR4S2 | OR4T1P | OR4V1P | OR4X1 | OR4X2 | OR51A1P | OR51A2 | OR51A3P | OR51A4 | OR51A6P | OR51A7 | OR51B2 | OR51B4 | OR51B5 | OR51B6 | OR51C1P | OR51D1 | OR51E1 | OR51E2 | OR51F1 | OR51F2 | OR51G1 | OR51G2 | OR51H1 | OR51I1 | OR51I2 | OR51J1 | OR51L1 | OR51M1 | OR51Q1 | OR51S1 | OR51T1 | OR51V1 | OR52A1 | OR52A4P | OR52A5 | OR52B2 | OR52B4 | OR52B6 | OR52D1 | OR52E1 | OR52E2 | OR52E4 | OR52E5 | OR52E6 | OR52E8 | OR52H1 | OR52I1 | OR52I2 | OR52J3 | OR52K1 | OR52K2 | OR52K3P | OR52L1 | OR52M1 | OR52N1 | OR52N4 | OR52N5 | OR52R1 | OR52W1 | OR52Z1P
